WO2007143112A2 - Procédés de diagnostic de troubles et de maladies liées aux récepteurs de la ryanodine et procédés d'identification de composés qui affectent les récepteurs de la ryanodine - Google Patents

Procédés de diagnostic de troubles et de maladies liées aux récepteurs de la ryanodine et procédés d'identification de composés qui affectent les récepteurs de la ryanodine Download PDF

Info

Publication number
WO2007143112A2
WO2007143112A2 PCT/US2007/012969 US2007012969W WO2007143112A2 WO 2007143112 A2 WO2007143112 A2 WO 2007143112A2 US 2007012969 W US2007012969 W US 2007012969W WO 2007143112 A2 WO2007143112 A2 WO 2007143112A2
Authority
WO
WIPO (PCT)
Prior art keywords
ryanodine receptor
calstabin
protein
sample
amount
Prior art date
Application number
PCT/US2007/012969
Other languages
English (en)
Other versions
WO2007143112A3 (fr
Inventor
Andrew Robert Marks
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/032405 external-priority patent/WO2007024717A2/fr
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Publication of WO2007143112A2 publication Critical patent/WO2007143112A2/fr
Publication of WO2007143112A3 publication Critical patent/WO2007143112A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2878—Muscular dystrophy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders

Definitions

  • the present invention relates to methods for diagnosing disorders and diseases associated with abnormal or defective ryanodine receptor function. These methods can be performed using a sample of lymphocytes and/or blood containing lymphocytes, from a subject, and are therefore far less invasive than methods that involve obtaining samples of cardiac muscle, skeletal muscle, or brain tissue, from subjects.
  • the invention provides methods of screening for compounds that affect ryanodine receptor function and that may be useful for treating disorders and diseases associated with abnormal or defective ryanodine receptor function. Such screening methods also utilize peripheral blood, containing lymphocytes.
  • Intracellular calcium (Ca 2+ ) regulation plays an important role in animal physiology.
  • ryanodine receptors Rost alkyloid ryanodine.
  • RyRs are ligand gated calcium channels that regulate the release of calcium ions from intracellular storage sites, such as sarcoplasmic reticulum (SR), and are especially important in neurons and muscle cells.
  • SR sarcoplasmic reticulum
  • RyRs are stimulated by a positive feedback mechanism that is known as calcium-induced calcium release, with a rise in intracellular free Ca + concentration triggering the release of even more Ca 2+ .
  • RyRl is preferentially expressed in skeletal muscle tissue
  • RyR2 is preferentially expressed in cardiac tissue
  • RyR3 is preferentially expressed in multiple areas, including the hippocampus, caudate/putamen, the olfactory bulb, and olfactory tubercle. More generally, RyRs have been observed within cell bodies, axons, dendrites, spines and dendritic shafts.
  • RyRs comprise four channel subunits, or monomers, in association with multiple regulatory proteins. Homomeric RyRs are well known. Skeletal muscle RyRl, for example, comprises four RyRl monomers. Cardiac muscle RyR2 comprises four RyR2 monomers. Heteromeric RyRs are also possible, however, as multiple receptor isoforms can be present in the same tissue.
  • the RyR subunits form a regulatory region via their cytosol-projecting domains. This region provides a scaffold that can interact with many cytosolic modulators, including channel binding proteins, kinases, and phosphatases.
  • the RyR channel and associated proteins constitute a macromolecular channel complex, which is modulated by extracellular and intracellular signals, such as those triggering muscle contraction and nerve activity.
  • calstabin FK506-binding protein or FKBP
  • FKBP12 calstabin-12
  • FKBP12.6 calstabin-2
  • Calstabin binding to RyR is stoichiometric, i.e., one calstabin protein per RyR subunit. Under physiological conditions, calstabin-1 binds selectively to RyRl and RyR3, and calstabin-2 binds predominantly with RyR2.
  • calstabin binding helps stabilize the RyR2 channel by decreasing its open probability, minimizing calcium leak into the cytoplasm and thereby preventing aberrant activation during the resting phase of the cardiac cycle. Calstabin binding also facilitates coupled gating between neighboring RyR2 channels, which is thought to be important for promoting efficient excitation-contraction in muscle.
  • CPVT catecholaminergic polymorphic ventricular tachycardia
  • skeletal muscle defects which are among the major symptoms accompanying heart failure and include shortness of breath (resulting from diaphragmatic weakness) and intolerance to exercise (resulting from limb muscle fatigue), implicate aberrant regulation of RyRl, which is preferentially expressed in skeletal muscle tissue.
  • Functional defects of RyRl channels in HF skeletal muscle are analogous to those of Ry R2 channels in HF myocardium, and include PKA-hyperphosphorylation of RyR and depletion of calstabin-1.
  • Mutations in the RyRl channel have also been linked to skeletal muscle diseases.
  • RyRl mutations account for most cases of malignant hyperthermia (MH) and central core disease (CCD), which are autosomal dominant disorders.
  • MH mutant RyRl channel has a phenotype similar to CPVT mutations in RyR2, including enhanced activity under resting conditions and Ca 2+ leak from the SR to the cytoplasm.
  • Perturbed RyR signaling has also been implicated in neurodegenerative disorders.
  • the presence of RyR antibodies in blood serum has been associated with myasthenia gravis, the most common primary disorder of neuromuscular transmission.
  • myasthenia gravis the most common primary disorder of neuromuscular transmission.
  • patients with myasthenia gravis come to the physician complaining of specific muscle weakness and not of generalized fatigue.
  • RyR dysfunction is also associated with Alzheimer's disease (AD). Elevated RyR3 levels are observed in brain tissues isolated from genetically modified mice that express mutant Presenilin 1 at normal levels.
  • levels of RyR3 are greatly increased in PC 12 cells overexpressing mutant human Presenilin 1.
  • exaggerated intracellular Ca 2+ levels have been associated with expression of AD mutations in young mice.
  • the present invention relates to methods for diagnosing disorders and diseases associated with abnormal or defective ryanodine receptor function.
  • the methods of the invention can be performed using a sample of blood , including but not limited to peripheral blood, white blood cells or lymphocytes, from a subject, and are therefore far less invasive than methods that involve obtaining samples of cardiac muscle, skeletal muscle, or brain tissue, from subjects.
  • the invention provides methods of screening for compounds that affect ryanodine receptor function and that may be useful for treating disorders and diseases associated with abnormal or defective ryanodine receptor function. Such screening methods also utilize blood samples such as blood containing lymphocytes.
  • aspects of the present invention include methods of monitoring disease progression by monitoring the composition and characteristics of the RyR protein complex, for example but not limited to the level of ryanodine phosphorylation in blood samples (e.g., peripheral blood, white blood cells or lymphocytes) from a subject that has or is at risk of developing a disease or condition associated with the ryanodine receptor.
  • Other aspects of the present invention include methods of monitoring disease progression by quantifying the amount of calstabin bound to a ryanodine receptor in blood samples (e.g., peripheral blood, white blood cells or lymphocytes) from a subject that has or is at risk of developing a disease or condition associated with the ryanodine receptor.
  • the present invention relates, in certain aspects, to methods for diagnosing disorders and diseases associated with abnormal or defective ryanodine receptor function that can be performed using a sample of lymphocytes from a subject, or a samples of peripheral blood containing lymphocytes from a subject, and are therefore far less invasive than methods that involve obtaining samples of cardiac muscle, skeletal muscle, or brain tissue, from subjects.
  • the invention provides methods of screening for compounds that affect ryanodine receptor function and that may be useful for treating disorders and diseases associated with abnormal or defective ryanodine receptor function.
  • screening methods also utilize lymphocytes obtained from a subject, or a samples of blood containing lymphocytes obtained from a subject.
  • the present invention provides methods of diagnosing diseases or disorders associated with abnormal ryanodine receptors or abnormal ryanodine receptor function in subject by obtaining a sample of blood from the subject (e.g. peripheral blood), or a sample of white blood cells, (e.g. lymphocytes) derived from a blood sample from the subject, and testing the ryanodine receptor in that sample to determine if the ryanodine receptor is abnormal such that it may be associated a some disease or disorder.
  • a sample of blood from the subject e.g. peripheral blood
  • white blood cells e.g. lymphocytes
  • Sources of lymphocytes or blood or blood cells that can be used in the context of the present invention include, but are not limited to, peripheral blood, bone marrow, lymph nodes, spleen, thymus, as well as all cell types that are obtainable from a peripheral blood sample.
  • lymphocytes examples include, but are not limited to, all lineages of mature and immature, normal and abnormal, functional and dysfunctional leukocytes, lymphocytes, T-lymphocytes (T-cells), B-lymphocytes (B-cells), white blood cells, osteoclasts, tumor cells, natural killer cells, leukocytes, granulocytes, peripheral blood mononuclear cells (PBMC), plasma, thrombocytes, basophils, macrophages and dendritic cells.
  • T-lymphocytes T-lymphocytes
  • B-cells B-lymphocytes
  • PBMC peripheral blood mononuclear cells
  • plasma thrombocytes
  • basophils macrophages and dendritic cells.
  • dendritic cells for each of the methods described herein, any of the above listed sources of cells can be used.
  • the methods of the invention utilize lymphocytes, and preferably the lymphocytes are in or from a source that can be obtained from a subject in
  • the present invention provides a method of diagnosing a disease or disorder associated with abnormal ryanodine receptor function in a test subject comprising: (a) obtaining a blood sample from a test subject, (b) determining the amount of a calstabin protein bound to a ryanodine receptor protein in the blood sample from the test subject, and (c) comparing the amount of the calstabin protein bound to the ryanodine receptor in the test subject to a control measurement for the amount of the calstabin protein bound to the ryanodine receptor, whereby a lower amount of calstabin protein bound to the ryanodine receptor in the test subject as compared to the control measurement indicates that the test subject may have a disease or disorder associated with abnormal ryanodine receptor function.
  • the control measurement may be determined by any suitable method, for example by: (a) obtaining a tissue sample containing a ryanodine receptor and a calstabin protein from a control subject known to have normal ryanodine receptor function, and (b) determining the amount of the calstabin protein bound to the ryanodine receptor protein in the tissue sample from the control subject, thereby giving a control measurement for the amount of the calstabin protein bound to the ryanodine receptor in a subject known to have normal ryanodine receptor function.
  • the control measurement may also be obtained from a prior measurement of the amount of calstabin protein bound to ryanodine receptor obtained using a ryanodine receptor known to have normal function and/or structure and/or normal interaction with calstabin.
  • the present invention provides a method of diagnosing a disease or disorder associated with abnormal ryanodine receptor function in a test subject comprising: (a) obtaining a blood sample from a test subject, (b) obtaining a blood sample from a control subject known to have normal ryanodine receptor function, (c) determining the amount of a calstabin protein bound to a ryanodine receptor protein in the peripheral blood sample from the test subject, (d) determining the amount of the calstabin protein bound to the ryanodine receptor protein in the peripheral blood sample from the test subject, and (e) comparing the amount of the calstabin protein bound to the ryanodine receptor in the test subject to the amount of the calstabin protein bound to the ryanodine receptor in the control subject, whereby a lower amount of calstabin protein bound to the ryanodine receptor in the test subject as compared to the control subject indicates that the test subject may have a disease or disorder
  • determining the amount of a calstabin protein that is bound to a ryanodine receptor protein may be performed by immunoprecipating the ryanodine receptor protein and detecting, and quantifying the amount of, the calstabin protein present in the immunoprecipated ryanodine receptor protein complex, or by immunoprecipating the calstabin protein and detecting, and quantifying the amount of, the ryanodine receptor protein present in the immunoprecipated calstabin protein complex.
  • the ryanodine receptor protein complex may be immunoprecipated using an anti-ryanodine receptor antibody, and/or the calstabin protein may be immunoprecipated using an anti-calstabin antibody.
  • an anti- calstabin antibody may be used to detect the presence of calstabin in an immunoprecipated ryanodine receptor protein complex.
  • an anti-ryanodine receptor antibody may be used to detect the presence of a ryanodine receptor in an immunoprecipated calstabin protein complex.
  • Methods of detecting proteins using antibodies are well known in the art, and any such method can be used.
  • the ryanodine receptor may be radiolabeled, and the amount of ryanodine receptor bound to calstabin is determined by detecting and quantifying the radiolabel.
  • the calstabin protein may be radiolabeled, and the amount of ryanodine receptor bound to calstabin may be determined by detecting and quantifying the radiolabel in the calstabin protein.
  • the ryanodine receptor may be fluorescently labeled, and the amount of ryanodine receptor bound to calstabin may be determined by detecting and quantifying the fluorescent label.
  • the calstabin protein may be fluorescently labelled, and the amount of ryanodine receptor bound to calstabin may be determined by detecting and quantifying the fluorescent label.
  • the present invention provides methods for detecting mutations in ryanodine receptors, such as RyRl, RyR2, and Ry R3 in peripheral blood samples, containing lymphocytes, obtained from a subject. Even if the ultimate effect of the RyR receptor mutation is primarily in a tissue such as heart, muscle, or the brain, the presence of a mutation in a RyR gene, or in a RyR cDNA, can be detected in a peripheral blood sample, thereby provididing an easier and less invasive method of detecting a RyR mutation than corresponding methods that use biopsy material from cardiac, muscle or brain tissue.
  • the present invention provides a method for detecting a mutation in a ryanodine receptor, comprising (a) obtaining a blood sample from the subject,
  • the present invention provides a method for detecting a mutation in a ryanodine receptor in a test subject, comprising: (a) obtaining a blood sample from the subject, (b) obtaining a DNA sample from the blood sample from the test subject,
  • the methods for detecting mutations provided herein can be used to detect mutations in genomic DNA or in samples of cDNA, such as cDNA generated by reverse transcription of mRNA obtained from the lymphocytes.
  • the mutations can be detected using any suitable method known in the art, such as standard nucleotide sequencing methods, PCR-based methods, restriction fragment length polymorphism analysis, and the like.
  • the nucleotide sequence of the wild type ryanodine receptor may be obtained from a public nucleotide sequence database, such as the Genbank database or the human genome database.
  • the nucleotide sequence of the wild type ryanodine receptor may be also obtained from publications in which the wild-type nucleotide sequence of a RyR is provided, or may also be obtained by sequencing a RyR gene of cDNA from an individual known to have a wild type version of that RyR gene.
  • the present invention provides amethod of determining the amount of ryanodine receptor phosphorylation in a test subject comprising: (a) obtaining a sample of blood from a test subject, (b) determining the amount of a phosphorylation of a ryanodine receptor protein in the blood sample, (c) comparing the amount of phosphorylation of the ryanodine receptor in the test subject to a control measurement of the amount of phosphorylation of a ryanodine receptor, whereby a higher amount of the ryanodine receptor phosphorylation in the test subject as compared to the control measurement indicates that the test subject has or is at risk of developing a ryanodine receptor hyperphosphorylation defect and has or is at risk of developing, a disease or disorder associated with ryanodine receptor hyperphosphorylation.
  • the control measurement may be made using any suitable method known in the art, for example the control measurement may be determined by: (a) obtaining a tissue sample containing a ryanodine receptor from a control subject known to have normal ryanodine receptor phosphorylation, and (b) determining the amount of phosphorylation of the ryanodine receptor protein in the tissue sample from the control subject, thereby giving a control measurement for the amount of phosphorylation of the ryanodine receptor in a subject known to have normal ryanodine receptor phosphorylation.
  • the control measurement may also be obtained from a prior measurement of the amount of phosphorylation of the ryanodine receptor obtained using a ryanodine receptor known to have normal phosphorylation, such as normal PKA phosphorylation.
  • the present invention provides a method of determining the level of ryanodine receptor phosphorylation in a test subject comprising: (a) obtaining a blood sample from a test subject, (b) obtaining a blood sample from a control subject known to have normal ryanodine receptor phosphorylation, (c) determining the amount of a phosphorylation of a ryanodine receptor protein in the blood sample from the test subject, (d) determining the amount of phosphorylation of the ryanodine receptor protein in the blood sample from the control subject, and (e) comparing the amount of phosphorylation of the ryanodine receptor in the test subject to the amount of phosphorylation of the ryanodine receptor in the control subject, whereby a higher amount of the ryanodine receptor phosphorylation in the test subject as compared to the control subject indicates that the test subject may have a ryanodine receptor hyperphosphorylation
  • the present invention provides a method for identifying, or screening for, an agent, such as a chemical compound, that enhances binding of a calstabin protein to a ryanodine receptor protein, or inhibits dissociation of a calstabin protein from a ryanodine receptor protein, comprising (a) obtaining a blood sample from a subject, (b) contacting a first portion of the blood sample with an agent that causes dissociation of a calstabin protein from a ryanodine receptor protein, (c) measuring the amount of a calstabin protein bound to a ryanodine receptor protein in the first portion of the blood sample, (d) contacting a second portion of the blood sample with an agent that causes dissociation of a calstabin protein from a ryanodine receptor protein and a test compound, (e) measuring the amount of the calstabin protein bound to the ryanodine receptor protein in the second portion of the blood sample,
  • an agent such as a
  • the present invention provides an in vivo method for identifying a chemical compound that enhances binding of a calstabin protein to a ryanodine receptor protein, or inhibits dissociation of a calstabin protein from a ryanodine receptor protein, comprising: (a) administering to an animal a physiologically effective amount of a regulating compound that decreases binding of a calstabin protein to a ryanodine receptor protein, or causes dissociation of a calstabin protein from a ryanodine receptor protein; (b) obtaining a first blood sample from the animal, (c) subsequently administering to the animal a physiologically effective amount of a regulating compound that decreases binding of a calstabin protein to a ryanodine receptor protein, or causes dissociation of a calstabin protein from a ryanodine receptor protein, and test compound, (d) obtaining a second blood sample from the animal, (e) measuring the
  • the present invention provides an in vivo method for identifying a compound that produces a change in calstabin binding to a ryanodine receptor, which method comprises: (a) administering to a first animal a physiologically effective amount of a regulating compound that regulates calstabin binding to a ryanodine receptor; (b) obtaining a first blood sample from the first animal, (c) measuring the amount of calstabin bound to the ryanodine receptor in the first blood sample; (d) administering to a second animal, which in one embodiment may be substantially genetically identical to the first animal, the same relative to weight amount of the regulating compound in combination with an amount of a test compound,(e) obtaining a second sample of blood from the second animal, (f) measuring the amount of calstabin bound to the ryanodine receptor in the second blood sample; and (g) comparing the measured amounts of calstabin bound to the ryanodine receptor in the first and the second blood
  • the regulating compound may be a beta-adrenergic agonist.
  • the beta-adrenergic agonist is isoproterenol or "ISO", as is used in Example 1.
  • the regulating compound may be an agonist of the cAMP pathway.
  • the agent is a 1,4, benzothiazepine compound, such as a 1 ,4, benzothiazepine compound that may be described by chemical Formula I described in the below detailed description.
  • Example 1 and Figure 1 show that such an assay can be used to demonstrate the efficacy of compounds ARM036 and ARM 064 on the RyRxalstabin interaction in lymphocytes obtained from a blood sample from rats. These two compounds are 1,4, benzothiazepine compounds.
  • the assay can also be used to dentify any class of agent that has the desired effect on a RyR protein or the RyRxalstabin interaction.
  • the compounds may be administered by any suitable route, such as orally, subcutaneously, or via an implanted osmotic pump.
  • the regulating compound is administered subcutaneously via an osmotic pump for at least about 3 days, or for at least about about 5 days.
  • the present invention provides a method of diagnosing a disease or disorder associated with leak of calcium through a ryanodine receptor in a test subject comprising: (a) obtaining a blood sample, containing lymphocytes, from a test subject, (b) obtaining a blood sample, containing lymphocytes, from a control subject known to have normal ryanodine receptor function, and (c) determining whether there is any calcium leak through the ryanodine receptor in the a blood samples obtained in the test subject and the control subject, whereby a higher level of calcium leak in the ryanodine receptor from the test subject as compared to the control subject, indicates that the test subject may have a disease or disorder associated with the leak of calcium through a ryanodine receptor.
  • the step of determining whether there is any calcium leak through the ryanodine receptor is performed using an electrophysiological recording technique, such as single channel patch clamp recording an the like.
  • calcium leak can be measured using a fluorescent intracellular calcium indicator or any other means known in the art for monitoring calcium flow through ion channels.
  • the blood sample can contain lymphocytes.
  • a sample of peripheral blood may be used.
  • a sample of bone marrow cells may be used.
  • a sample of lymphocytes may be used.
  • a buffy coat preparation may be produced from a blood sample using any method known in the art, such as the method described in the accompanying Example.
  • the blood/lymphocyte sample may comprise B cells, T cells, natural killer cells, or any combination thereof, or any other type of lymphocyte known in the art that expresses at least one ryanodine receptor.
  • the calstabin protein may be calstabin 1 or calstabin 2
  • the ryanodine receptor protein may be RyRl, RyR2, or RyR3, or any combination thereof.
  • the test subject, and the control subject if one is used may be any animal for which it is desired to detect or diagnose a disease or disorder, or detect a mutation, or in which it is desired to screen the efficacy of certain compounds.
  • the subjects are mammals.
  • the subjects are humans.
  • the preferred subjects may be rodents such as mice.
  • the control subject and the test subject are preferably from the same species.
  • the diseases and disorders referred to may be any disease or disorder associated with altered function or activity of a ryanodine receptor, or associated with a mutation in a ryanodine receptor, or associated with an altered interaction between a ryanodine receptor and a calstabin protein.
  • diseases and disorders include, but are not limited to, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome.
  • Cardiac disorders and diseases include, but are not limited to irregular heartbeat disorders and diseases, exercise-induced irregular heartbeat disorders and diseases, sudden cardiac death, exercise-induced sudden cardiac death, congestive heart failure, chronic obstructive pulmonary disease, and high blood pressure.
  • Irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmias, atrial and ventricular fibrillation, atrial and ventricular tachyarrhythmias, atrial and ventricular tachycardias, catecholaminergic polymorphic ventricular tachycardia (CPVT), and exercise-induced variants thereof.
  • Skeletal muscular disorders and diseases include, but are not limited to, skeletal muscle fatigue, exercise- induced skeletal muscle fatigue, myopathies, muscular dystrophy, certain types of skelelal muscle bladder disorders, and incontinence associated with skeletal muscle function.
  • Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, memory disorders, and age-dependent memory disorders.
  • the present invention provides a method of assessing the efficacy of drug treatment, by performing one of the assays described above, such as those used to detect the RyRxalstabin interaction at various points in time before, during, and after drug therapy, thereby monitoring the efficacy of the drug therapy.
  • the present invention provides a method of monitoring disease progression, by performing one of the assays described above, such as those used to detect the RyRxalstabin interaction or those used to evaluate the level of ryanodine phosphorylation, at various points before or following diagnosis of the disease, thereby monitoring the progression of the disease.
  • the present invention provides an in vivo method for identifying a compound that produces a change in calstabin binding to a ryanodine receptor, which method comprises administering a test drug to an animal known to have hyperphosphorylated ryanodine; obtaining a sample of blood cells from the animal; measuring calstabin binding to ryanodine receptor in said animal; and comparing the amount of calstabin bound to ryanodine in the animal to the amount of calstabin bound to ryanodine in an untreated control animal known to have hyperphosphorylated RyR to determine whether the test compound changes calstabin binding to such ryanodine receptor.
  • Figure 1 demonstrates provides data from an in vivo rat assay in which isoproterenol was used to destabilize binding of calstabin to RyRs, and then two test compounds, namely the 1,4, benzothiazpeines S36 and S64 were tested to see if they increased binding of calstabin to the RyRs.
  • Calstabin binding was measured by immunoprecipitation of RyR from on buffy coat samples prepared from peripheral blood, and blotting using calstabin antibodies.
  • the term “about” or “approximately” means within an acceptable range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean a range of up to 20%, up to 10%, up to 5%, and up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, within 5-fold, within 2-fold, of a value.
  • the term "treating" or "treatment” of a disorder or disease includes (1) preventing or delaying the appearance of clinical symptoms of the disorder or disease developing in a mammal that may be afflicted with or predisposed to the disorder or disease but does not yet experience or display clinical or subclinical symptoms of the disorder or disease; or (2) inhibiting the disorder or disease, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or sub-clinical symptom thereof; or (3) relieving the disease or disorder, i.e., causing regression of the disease or disorder or at least one of its clinical or sub-clinical symptoms.
  • the term "patient” or “subject” or “animal” refers to all members of the animal kingdom, particularly vertebrates, and especially mammals e.g., mice, rats, pigs, cats, and dogs. In the context of therapeutic and diagnostic applications, the term also includes humans.
  • diseases or disorders or conditions associated with a ryanodine receptor includes disorders and diseases that can be treated by modulating the RyR receptors that regulate calcium channel functioning in cells.
  • disorders, diseases and conditions include, without limitation, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hypethermia, diabetes, sudden infant death syndrome, and muscle fatigue (e.g., exercise-induced muscle fatigue, or muscle fatigue induced by a disease or disorder).
  • cardiac disorders and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure.
  • irregular heartbeat disorders and diseases and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaniinergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof.
  • CPVT catecholaniinergic polymorphic ventricular tachycardia
  • Examples of skeletal muscular disorder and diseases include, but are not limited to, muscle fatigue that results from pathologies, illnesses, diseases, disorders or conditions that are associated with the RyR receptors that regulate calcium channel functioning in cells.
  • Examples of such disorders and conditions include, but are not limited to, cardiac disease or disorder, defective skeletal muscle function, HIV Infection, AIDS, muscular dystrophy, cancer, malnutrition, exercise-induced muscle fatigue, age-associated muscle fatigue, renal disease, renal failure, bladder disorders, incontinence, malignant hypothermia, and central core disease.
  • Examples of cognitive disorders and diseases include, but are not limited to, forms of memory loss, age-dependent memory loss, and neurodegenerative disorders, including Alzheimer's Disease and myasthenia gravis.
  • the term "inhibiting dissociation” includes blocking, decreasing, inhibiting, limiting or preventing the physical dissociation or separation of an FKBP subunit (or calstabin protein) from a RyR molecule (e.g., phosphorylated RyR molecule), and blocking, decreasing, inhibiting, limiting or preventing the physical dissociation or separation of the RyR molecule from an FKBP subunit (or calstabin protein).
  • the term "increasing binding” or "enhancing binding” or “enhancing reassociation” includes enhancing, increasing, or improving the ability of RyR (e.g., phosphorylated RyR) to associate physically with FKBP/calstabin (e.g., binding of approximately two fold or, approximately five fold, above the background binding of a negative control) in a tissue sample or cells of the subject and enhancing, increasing or improving the ability of FKBP/calstabin to associate physically with RyR (e.g., binding of approximately two fold, or, approximately five fold, above the background binding of a negative control) in cells of the subject.
  • RyR e.g., phosphorylated RyR
  • RyR refers to a ryanodine receptor and includes RyRl, RyR2, and RyR3 subtypes of the ryanodine receptor. It also includes an "RyR protein” and an “RyR analog.”
  • An "RyR analog” is a functional variant of the RyR protein, having RyR biological activity that has about 60%, 70%, 80%, 85%, 90%, 95%, 97% or greater amino- acid-sequence homology with the RyR protein.
  • calstabin includes calstabin-1 (FKBP 12) or calstabin-2 (FKBP 12.6). It also includes a “calstabin protein,” “calstabin polypeptide,” and “calstabin analog.”
  • a “calstabin analog” is a functional variant of the calstabin protein, having calstabin biological activity, e.g., ability to bind RyR that has about 60%, 70%, 80%, 85%, 90%, 95%, 97% or greater amino-acid-sequence homology with the calstabin protein.
  • “RyR- bound calstabin” therefore includes RyRI-bound calstabin-1 (FKBP 12), RyR2-bound calstabin-2 (FKBP12), and RyR3-bound calstabin-1 (FKBP12).
  • regulatory compound and “regulating compound” have the same meaning.
  • regulatory compound refers to a compound which modulates the interaction between calstabin and ryanodine.
  • the term "modulate” includes decreasing, increasing, inhibiting, enhancing, stabilizing, and/or restabilizing an effect.
  • a regulating compound such as a beta agonist
  • a test compound can modulate this effect by inhibiting the regulating compound-induced dissociation of calstabin and RyR; and/or by increasing binding between calstabin and RyR following such regulating compound-induced dissociation; stabilizing the RyR-calstabin complex, and even restabilizing the RyR complex by promoting the reassociation of calstabin to RyR.
  • Calstabin binding to RyR can be regulated by covalent modifications to RyR.
  • calstabin-2 binding to RyR2 is regulated by PKA phosphorylation of Ser2809 in RyR2.
  • PKA phosphorylation of RyR2 decreases the binding affinity of calstabin-2, causing calstabin-2 dissociation and increasing RyR2 open probability (Po) and its sensitivity to Ca + -dependent activation.
  • PKA-phosphorylated RyR is an important part of the "fight or flight" response, by which the sympathetic nervous system (SNS), in response to stress or exercise, enhances myocardial contractility and increases cardiac output.
  • SNS sympathetic nervous system
  • the activated sympathetic nervous system produces catecholamines (noradrenalin and adrenalin), which stimulate a beta adrenergic signaling cascade that results in a transient increase in PKA-phosphorylation of RyR2 at S2809.
  • catecholamines noradrenalin and adrenalin
  • this modification alters the biophysical properties of the channel such that there is an increased SR calcium release for a given calcium trigger.
  • these calstabin mutants can rescue defective channel function in PKA-hyperphosporylated RyR2, and they complement defective channel function in a mutant RyR2 (S2808D) that mimics constitutive PKA phosphorylation.
  • S2808D defective channel function in a mutant RyR2
  • JTV519 a 1,4- benzothiazepine derivative that enhances the binding affinity of calstabin-2 for RyR2 even when the channel is PKA hyperphosphorylated.
  • JTV519 slowed HF progression by inhibiting RyR2 hyperactivity and intracellular calcium leak. Masafumi et al., Circulation. 2003; 107:477-484.
  • JTV519 increased calstabin-1 binding to RyRl and improved skeletal muscle function. Wehrens et al., Proc. Natl. Acad. ScL 2005; 102:9607-9612; U.S. Pat. No. 6,489,125. In calstabin-2 haploinsufficient mice, JTV519 prevented diastolic Ca 2+ leak and catecholamine-induced ventricular arrhythmias by increasing calstabin-2 binding to PKA-phosphorylated RyR2.
  • the present invention is directed to the use of an in vivo animal model, for example a mouse or rat model, which mimics the effect of chronic sympathetic stimulation of ryanodine receptors in the heart or skeletal muscles, including phosphorylation by protein kinase A and dissociation of calstabin subunits.
  • Chronically administered beta-adrenergic agonists for example but not limited to isoproterenol ("ISO), by osmotic minipump, or any other method for in vivo delivery of a drug (e.g. IV and IP injection), mimics chronic sympathetic nervous system activation as occurring in disease processes in the heart, skeletal muscle, or other organs.
  • chronic administration of isoproterenol to an animal, such as a rat or mouse, by osmotic pump infusion implanted subcutaneous Iy for one week depletes calstabins from RyR. This depletion can be detected in peripheral blood samples, and buffy coat preparations made therefrom, thereby providing a non-invasive animal model by which this effect can be studied, and by which compounds that may increase binding of calstabin to RyRs can be screened for or studied. Such compounds are useful for the treatment of disorders and conditions associated with disruption of the RyRrcalstabin interaction.
  • beta-adrenergic agonist for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14 days, to an animal leads to increased RyR phosphorylation, and decreased calstabin binding.
  • the agonist is isoproterenol.
  • the effects of continuous or chronic administration of beta-adrenoreceptor agonist can be examined and quantified by isolating peripheral blood, containing lymphocytes, from the animal and measuring the levels of calstabin bound to RyR complexes.
  • the effects of drug treatment on the levels of calstabin bound to RyR complexes can also be studied, in order to identify new agents that may be useful for treatment of diseases and disorders affecting RyR function.
  • the method can be used to identify a therapeutically useful 1 ,4-benzothiazepine derivative as represented by Formula I:
  • R 4 is selected from the group consisting of H, alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, heteroaryl, and heterocyclyl; wherein each alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, heteroaryl, and heterocyclyl may be substituted or unsubstituted;
  • R 5 is selected from the group consisting Of-NRi 5 R] 6, -(CH 2 )zNR
  • 6 > -NHOH, - OR 15 , -C(O)NHNR 15 Ri 6 , -CO 2 R 15 , -C( O)NR 15 R 16 , -CH 2 X, acyl, alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted, and wherein z is 1 , 2, 3, 4, 5, or 6;
  • R 6 is selected from the group consisting of-OR15, -NHNR ]5 Ri 6 , -NHOH, -NRi 5 Ri 6 , -CH 2 X, 25 acyl, alkenyl, alkyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
  • R 7 is selected from the group consisting of-ORi 5 , -NRi 5 Ri 6 , -NHNRi 5 Ri 6 , -NHOH, -CH 2 X, alkyl, alkenyl, alkynyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkenyl, alkynyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
  • Rg and R 9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
  • 2, Ri 3 , and R14 independently are selected from the group consisting of H, OH, NH 2 , - NHNH 2 , -NHOH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
  • Ri 5 and R) 6 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH 2 , alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally Ri 5 and Ri 6 together with the N to which they are bonded may form a heterocycle which may be substituted; and the nitrogen in the benzothiazepine ring may optionally be a quaternary nitrogen, and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts
  • the invention provides in vivo methods for determining the composition and characteristics of the RyR complex, for example but not limited to the phosphorylation state, in an animal.
  • the animal is suffering from a disease or disorders associated with RyR receptor complex, such as a cardiac, skeletal muscle, or neurological disease or disorder associated with abnormal structure or function of the RyR complex.
  • the methods comprise measuring a change in the binding of a calstabin to a ryanodine receptor.
  • the method comprises administering to an animal a physiologically effective amount of a compound that regulates calstabin binding to a ryanodine receptor and measuring the calstabin binding to the ryanodine receptor in a blood sample from the animal.
  • the animal can be a mammal, including a human, but also other animals, especially mammals such as mice, rats, dogs, and pigs can be used.
  • the measurement of calstabin binding to RyR in an animal treated with the compound, i.e., an animal to which the compound is administered is compared with calstabin binding to RyR in an untreated animal, i.e., an animal to which the compound is not administered.
  • the invention provides in vivo methods for identifying compounds that modulate binding of a calstabin to a ryanodine receptor and that can be used to treat diseases associated with RyRs.
  • the methods involve administering to an animal, e.g., a mouse or another mammal such as a rat, a dog, or a pig, a physiologically effective amount of a regulating compound that regulates or decreases calstabin binding to a ryanodine receptor and then measuring calstabin binding to such receptor in that animal; administering to another, similar animal the same amount of the regulating compound in combination with an amount of a test compound and measuring calstabin binding to a ryanodine receptor in that animal; and comparing the measured calstabin binding in a blood sample from each animal to determine whether the test compound changes or increases calstabin binding to the ryanodine receptor.
  • an animal e.g., a mouse or another mammal such as a rat, a dog,
  • the difference in binding of the calstabin to the ryanodine receptor between the animals indicates whether and to what extent the test compound modulates binding of the calstabin to the ryanodine receptor.
  • the administration and measurements in each animal can be made in any desired order, sequentially or at the same time, and by any mode of administration (e.g., oral or subcutaneous via an osmotic pump).
  • the present methods can be used to screen, in vivo, a plurality of compounds to identify a compound that modulates binding of a calstabin to a ryanodine receptor, by administering the regulating compound and the test compound to a plurality of animals and comparing the calstabin binding measurement in each of these animals to that measured from an animal that received only the regulating compound.
  • multiple forms of a compound can be tested in separate animals or groups of animals, together with the appropriate positive and negative controls, such that overall comparison of calstabin levels in various forms of a compound can be made in a simple and effective manner.
  • the compound that regulates calstabin binding to a ryanodine receptor can be any agent that can regulates RyR function in vivo.
  • the regulating compound is capable of decreasing calstabin binding to RyR.
  • the regulating compound is able to disrupt calstabin-2 binding to RyR2, especially in cardiac muscle tissue.
  • the regulating compound is able to disrupt calstabin-1 binding to RyRl, especially in skeletal muscle tissue.
  • the regulating compound is able to disrupt calstabin-1 binding to RyR3, especially in the brain.
  • the compound is a beta-agonist, such as the synthetic beta-agonist, e.g., isoproterenol.
  • beta-adrenergic receptors Upon stimulation, beta-adrenergic receptors trigger signaling pathways that can lead to decreased calstabin binding to RyR.
  • this pathway involves G protein-coupled receptors that activate adenylyl cyclase, inducing production of the second messenger cyclic AMP, which in turn can activate protein kinase A (PKA).
  • PKA protein kinase A
  • regulating compounds include agents that modulate steps in the beta-adrenergic signaling pathway.
  • the compound is an activator of G-proteins or a stimulator of PKA, such as forskolin.
  • the regulating compound is administered to a subject by contacting target tissue cells (e.g., cardiac cells) in vivo.
  • target tissue cells e.g., cardiac cells
  • the regulatory compound contacts the tissue directly, for example, by binding to a surface receptor or by stimulating adenylate cyclase.
  • the regulating compound can contact the tissue indirectly.
  • the regulating compound itself triggers beta-adrenergic signaling by mimicking the action of preganglionic cells in the SNS, and thereby activates beta-adrenergic signaling through the sympathetic postganglionic fibers that innervate target organs.
  • the regulating compound is administered to the subject in a physiologically effective amount that can disrupt the interaction between calstabin and RyR, e.g., the interaction between calstabin-2 and RyR2.
  • the effective amount can be readily determined by the skilled artisan based on standard criteria, such as the delivery method, administration route, established titration studies, and methods and assays disclosed herein.
  • the compound is delivered to the subject via blood, its concentration in the blood over time can be determined by removing samples and analyzing the levels in the plasma.
  • the regulating compound is a beta agonist, for e.g.
  • isoproterenol and has an effective amount of approximately 0.5 mg/kg/hr, when administered by an osmotic pump that has been implanted subcutaneously in a mouse.
  • the beta agonist is chronically administered to the subject, for example, for three to five days.
  • in vivo binding of calstabin to RyR can be determined by obtaining a blood sample which contains lymphocytes, making a buffy coat preparation therefrom, immunoprecipitating RyR complexes from the sample, and analyzing the complexes for the presence of calstabin. Levels of phosphorylated-RyR and total RyR can also be determined.
  • Protein levels can be assayed in a blood or buffy coat sample by standard methods and techniques, including those readily determined from the art (e.g., immunological techniques, hybridization analysis, Immunoprecipitation, Western-blot analysis, fluorescence imaging techniques, and/or radiation detection, etc.), as well as any assays and detection methods disclosed herein.
  • standard methods and techniques including those readily determined from the art (e.g., immunological techniques, hybridization analysis, Immunoprecipitation, Western-blot analysis, fluorescence imaging techniques, and/or radiation detection, etc.), as well as any assays and detection methods disclosed herein.
  • Test compounds include any agent that hasan effect on, or is to be tested to determine if it has an effect on, RyR channel function, and more particularly, on the interaction of RyR with calstabin.
  • Test compounds include chemicals, small molecules, proteins, peptides, antibodies, and RNA-regulating agents, including those based on anti sense, ribozyme, and RNAi technologies.
  • test compounds are 1 ,4-benzothiazepine derivatives represented by Formula I, as described above.
  • test compounds may be administered to the subject in an amount effective to change, limit or prevent a decrease in, or increase, the level of RyR-bound calstabin in the subject, particularly, in cells of the subject.
  • the effective amount is readily determined by a skilled artisan, based on known procedures, consideration of the administrative routes, analysis of titration curves, and methods and assays disclosed herein.
  • a suitable amount of compounds having or based on a 1,4-benzothiazepine structure ranges from about 5 mg/kg/day to about 20 mg/kg/day, and/or is an amount sufficient to achieve plasma levels ranging from about 5 ng/ml to about 1000 ng/ml.
  • the amount of a compound of Formula I ranges from about 10 mg/kg/day to about 20 mg/kg/day.
  • the test compound is administered as is, without further processing.
  • the compound can be administered in a pharmaceutical formulation, e.g., in admixture with a suitable pharmaceutical excipient, diluent, or carrier selected with regard to the intended route of administration and standard pharmaceutical practices.
  • the invention provides a pharmaceutical composition or formulation comprising at least one test compound, or a pharmaceutically acceptable derivative thereof, as the active ingredient in association with a pharmaceutically acceptable excipient, diluent and/or carrier that is compatible with the other ingredients of the formulation and that is not deleterious to the recipient thereof.
  • the test compound modulates binding of a calstabin to a ryanodine receptor by increasing the binding of the calstabin to the RyR.
  • the test compound is able to increase binding of calstabin-2 to RyR2, especially in cardiac muscle tissue.
  • the test compound is able to increase binding of calstabin- 1 to RyRl, especially in skeletal muscle tissue.
  • the test compound is able to increase binding of calstabin- 1 binding to RyR3, especially in the brain. Therefore, the test compound can limit or prevent decreased levels of RyR-bound calstabin in cells of a subject, or increase such levels, by increasing the ability of calstabin to bind to phosphorylated RyR.
  • Regulating compounds and test compounds are administered to a subject by contacting target tissues cells, e.g., cardiac muscle cells, in vivo, using any suitable technique, including known techniques used to introduce and administer proteins, nucleic acids, small molecules, and other drugs.
  • suitable technique including known techniques used to introduce and administer proteins, nucleic acids, small molecules, and other drugs.
  • methods of administering the compound include, without limitation, absorption, electroporation, immersion, injection, liposome delivery, transfection, transfusion, vectors and other drug-delivery vehicles and other methods, including oral delivery and subcutaneous administration.
  • a particular tissue or portion of the subject When administration to a particular tissue or portion of the subject is desired, e.g., when target cells are localized to a particular tissue or portion of a subject, it is desirable to introduce the compounds directly to the target tissue or portion, by injection or by some other suitable means (e.g., by introducing the compounds into the blood or another body fluid).
  • suitable means include intravenous, intra-arteriole, intramuscular, intradermal, subcutaneous, intraperitoneal, transmucosal, and transdermal routes.
  • the compound is administered to the subject subcutaneously.
  • the compound is administered to the subject via an implanted osmotic infusion pump that contains the compound.
  • the osmotic pump is implanted subcutaneously, allowing the compound to target multiple tissues in the body through the bloodstream. If desired, plasma samples can be isolated over time and analyzed to determine the concentration of the compound in the blood.
  • Other configurations for osmotic pump infusion are also contemplated.
  • the pump can be implanted intraperitoneally or connected to a catheter to target the compounds to a specific tissue or organ by microperfusion. Such targets include the venous or arterial systems, brain, muscles, spinal cord, or other organs and tissues.
  • Osmotic pumps can also be implanted serially if a longer period of perfusion or microperfusion is desired.
  • osmotic pumps containing a regulating or test compound provide a versatile means for inducing a measurable change in calstabin binding to RyR in any suitable animal system.
  • Osmotic pump implantation can be used with various animals, including fish, frogs, birds, and many mammals, including rats, guinea pigs, rabbits, cats, dogs, pigs, goats, sheep, horses, and primates, including humans.
  • the compound, especially the test compound is administered orally.
  • the compound when orally administering to small animals, the compound can be administered by gavage feeding. Oral administration is especially convenient and preferred when administering the compound to humans.
  • the regulating compound and the test compound can be administered by the same or different routes, as desired.
  • the regulating compound can be chronically administered by an implanted osmotic pump, and the test compound can be delivered by oral administration.
  • both the regulating compound and the test compound can be administered by an implanted osmotic pump.
  • the compound e.g., the test compound
  • the test compound can be administered by any dosing regimen known in the art, including, but not limited to once daily, twice daily or thrice daily.
  • the test compound can be administered concurrently with the regulatory compound (e.g., for 3, 4 or 5 days, by any mode of administration), or it can be administered before of after the regulatory compound.
  • the test compound is administered following administration of the regulatory compound for a time period sufficient to elicit a biological effect such as RyR phosphorylation and concomitant decrease in calstabin binding to RyR.
  • the present invention also provides a method of monitoring the progression of a disease or disorder associated with abnormal ryanodine receptor structure or function comprising: (a) obtaining a first blood sample from a test subject, (b) obtaining a second blood sample from the test subject, wherein the second sample is obtained after the first sample, (c) determining the amount of a calstabin protein bound to a ryanodine receptor protein in the first sample and the second sample; and (d) comparing the amount of the calstabin protein bound to the ryanodine receptor in the first and second sample, whereby a lower amount of calstabin protein bound to the ryanodine receptor in the second sample as compared to the first sample indicates progression of the disease or diosrder in the subject. Variations on this method will be apparent to those skilled in the art and can be used to monitoring the progression of a disease or disorder associated with abnormal ryanodine receptor structure or function.
  • the present invention also provides a method of monitoring drug efficacy in a subject comprising: (a) obtaining a first blood sample from a test subject who has a disease or disorder associated with abnormal ryanodine receptor, (b) administering a drug to said subject, (c) obtaining a second blood sample from the test subject, (d) determining the amount of a calstabin protein bound to a ryanodine receptor protein in the first sample and the second sample; and (e) comparing the amount of the calstabin protein bound to the ryanodine receptor in the first and second sample, whereby a higher amount of calstabin protein bound to the ryanodine receptor in the second sample as compared to the first sample is indicative of the efficacy of the drug in increasing theamount of calstabin protein bound to the ryanodine receptor.
  • efficacy of the drug in increasing the amount of calstabin protein bound to the ryanodine receptor may be indicative of efficacy in treating the disease or disorder associated with abnormal ryanodine receptor complex structure or function.
  • efficacy refers to any detectable increase in binding of calstabin to the ryanodine receptor and/or any detectable improvement or lessening of any symptom of disease or disorder associated with abnormal ryanodine receptor complex structure or function.
  • Rats were maintained and studied according to approved protocols.
  • the synthetic beta-adrenergic agonist, isoproterenol (ISO) was obtained from Sigma (165627) and prepared as a 100 mg/ml stock in water. Lysis buffer was made by adding sucrose (1 mM), dithiothreitol (320 mM), and 1 protease inhibitor tablet (10X) to 10 ml stock solution (10 mM HEPES, 1 mM EDTA, 20 mM NaF, 2 mM Na3VO4).
  • Rats were continuously infused for five days with 10 mg/ml isoproterenol (10 ⁇ l/hr) by means of a subcutaneously implanted osmotic infusion pump (Alzet MiniOsmotic pump, Model 2001, Durect Corporation, Cupertino, CA).
  • the osmotic pump was held vertically and 200 ⁇ l drug solution was injected into the pump via a 2 ml syringe (attached to a cannula) that contained an excess of drug solution (2.2ml per pump). The drug solution was injected slowly downward, while the syringe was slowly lifted, until the pump was overfilled. Overflow of displaced fluid upon capping the pump confirmed that the pump was properly filled.
  • the loaded osmotic pumps were implanted subcutaneously by the following steps.
  • the recipient rat was anesthetized with 1.5-2% isofluorane in O2 administered at 0.6 L/min, and its weight was then measured and recorded.
  • the rat was then placed chest-down on styrofoam, its face in the nose cone. The fur was clipped on the back of the neck, extending behind the ears to the top of the head. The area was wiped gently with 70% alcohol, and a small incision was made at the midline on the nape of head/neck.
  • a suture holder was swabbed with alcohol, inserted into the cut, and opened to release the skin from the underlying tissue.
  • this opening was extended back to the hindquarters.
  • the loaded pump was inserted into the opening, with its release site positioned away from the incision, and was allowed to settle underneath the skin with minimal tension.
  • the incision was closed with 5.0 nylon suture, requiring about 5-6 sutures, and the area was wiped gently with 70% alcohol. Following surgery, mice were placed in individual cages to minimize injury and possible activation of the sympathetic nervous system.
  • ARM036 and ARM064 are 1,4, benzothiazepines, the structures of which are provided in published PCT application WO 07/024717 (PCT/US06/32405). In the following description, these compounds are referenced with a corresponding compound number, in which the prefixes "S” and “ARM” are used interchangeably.
  • compound “S36” is the same compound "ARM036” and compound “S64” is the same as "ARM064.”
  • Lymphocytes from 4 rats were combined and lysed in 0.25 ml RIPA Buffer (50 mM Tris-HCl pH 7.4, 0.9% NaCl, 5.0 mM NaF, 1.0 mM Na3VO4, 1.0% Triton-XIOO, and protease inhibitors) by passing through a 20 gauge needle 20 times. Samples were centrifuged at 2,500 x g to remove cellular debris. The supernatant was divided into 4 equal parts. The sample was resuspend in a total of 0.5 ml of RIPA buffer.
  • RIPA Buffer 50 mM Tris-HCl pH 7.4, 0.9% NaCl, 5.0 mM NaF, 1.0 mM Na3VO4, 1.0% Triton-XIOO, and protease inhibitors
  • RyRl, RyR2, or RyR3 proetins are then immunoprecipitated using isoform specific antibodies (1:250 dilution), and the immunoprecipitates are analyzed for total RyR, PKA phosphorylated RyR, and calstabin using IR labeled secondary antibodies and the Odyssey Infrared Imaging System (LICOR Biosciences, Lincoln NE).
  • isoproterenol treatment alone increased RyR phosphorylation in the rat lymphocytes, as can be seen by comparing the "Control" (no ISO) lane with the "Vehicle” (ISO but no test compound) lane in each panel. Further, isoproterenol treatment alone led to decreased calstabin levels. Notably, test compounds S36 and S64 led to enhanced calstabin binding to both RyRl and RyR2 in the lymphocyte/buffy coat samples.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés de diagnostic de troubles et de maladies liées à la fonction des récepteurs de la ryanodine et/ou à des mutations des récepteurs de la ryanodine. La présente invention concerne également des procédés d'identification de composés qui affectent la fonction des récepteurs de la ryanodine et qui peuvent être utiles pour traiter des troubles et des maladies liées à une fonction anormale ou défectueuse des récepteurs de la ryanodine, ainsi que divers autres procédés. Ces procédés peuvent être mis en œuvre en utilisant des échantillons de sang périphérique contenant des lymphocytes et ils sont donc beaucoup moins invasifs que les procédés impliquant l'obtention d'échantillons provenant d'autres sources.
PCT/US2007/012969 2006-06-02 2007-06-01 Procédés de diagnostic de troubles et de maladies liées aux récepteurs de la ryanodine et procédés d'identification de composés qui affectent les récepteurs de la ryanodine WO2007143112A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US81074806P 2006-06-02 2006-06-02
US60/810,748 2006-06-02
USPCT/US2006/032405 2006-08-17
PCT/US2006/032405 WO2007024717A2 (fr) 2005-08-25 2006-08-17 Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr
US86655606P 2006-11-20 2006-11-20
US60/866,556 2006-11-20
US90434807P 2007-02-28 2007-02-28
US60/904,348 2007-02-28

Publications (2)

Publication Number Publication Date
WO2007143112A2 true WO2007143112A2 (fr) 2007-12-13
WO2007143112A3 WO2007143112A3 (fr) 2008-03-13

Family

ID=38802091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/012969 WO2007143112A2 (fr) 2006-06-02 2007-06-01 Procédés de diagnostic de troubles et de maladies liées aux récepteurs de la ryanodine et procédés d'identification de composés qui affectent les récepteurs de la ryanodine

Country Status (1)

Country Link
WO (1) WO2007143112A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2015121500A1 (fr) * 2014-02-17 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions pharmaceutiques destinées à être utilisées dans le traitement de la dysfonction diaphragmique induite par ventilation mécanique
WO2016206030A1 (fr) * 2015-06-25 2016-12-29 谢小冬 Utilisations de marqueur moléculaire dans le dépistage précoce de la mort subite
CN111089971A (zh) * 2019-12-11 2020-05-01 浙江大学 一种膜电位调控下的蛋白相互作用定量检测装置
WO2021227056A1 (fr) * 2020-05-15 2021-11-18 清华大学 Lymphocyte t, procédé de préparation de ce dernier et ses applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780608B1 (en) * 1997-05-28 2004-08-24 Boehringer Ingelheim International Gmbh Human type 3 ryanodine receptor protein and DNA molecules coding therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780608B1 (en) * 1997-05-28 2004-08-24 Boehringer Ingelheim International Gmbh Human type 3 ryanodine receptor protein and DNA molecules coding therefor

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2015121500A1 (fr) * 2014-02-17 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions pharmaceutiques destinées à être utilisées dans le traitement de la dysfonction diaphragmique induite par ventilation mécanique
WO2016206030A1 (fr) * 2015-06-25 2016-12-29 谢小冬 Utilisations de marqueur moléculaire dans le dépistage précoce de la mort subite
CN111089971A (zh) * 2019-12-11 2020-05-01 浙江大学 一种膜电位调控下的蛋白相互作用定量检测装置
CN111089971B (zh) * 2019-12-11 2021-01-15 浙江大学 一种膜电位调控下的蛋白相互作用定量检测装置
WO2021227056A1 (fr) * 2020-05-15 2021-11-18 清华大学 Lymphocyte t, procédé de préparation de ce dernier et ses applications

Also Published As

Publication number Publication date
WO2007143112A3 (fr) 2008-03-13

Similar Documents

Publication Publication Date Title
JP5274831B2 (ja) リアノジンレセプタ（ＲｙＲ２）の漏れを標的とする、新規な抗−不整脈性及び心不全用薬剤及びその使用
US7632815B2 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
JP2011504474A (ja) アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用
CN101360999B (zh) 眼内压调节早期基因及其用途
TW200410672A (en) NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
AU2005238389B2 (en) Muscle relaxation accelerator and therapeutic agent for muscular tissue diseases such as muscle relaxation failure
WO2003037365A1 (fr) Procedes et compositions pour traiter la fuite vasculaire au moyen du facteur de croissance hepacytotaire
US20030134331A1 (en) Controlling pathways that regulate muscle contraction in the heart
WO2007143112A2 (fr) Procédés de diagnostic de troubles et de maladies liées aux récepteurs de la ryanodine et procédés d'identification de composés qui affectent les récepteurs de la ryanodine
US6248549B1 (en) Methods of modulating muscle contraction
AU2004253523A1 (en) Methods for treating and preventing cardiac arrhythmia
KR20060110290A (ko) 운동-유도성 심부정맥의 치료 및 예방을 위한 화합물 및방법
US20230032239A1 (en) A method of treatment in predisposed subjects for lmna-related dilated cardiomyopathy
US20070208074A1 (en) Methods and compositions for treating and preventing tumors
JP2007024705A (ja) リアノジン受容体安定化剤のスクリーニング方法
EP1272517B1 (fr) Matiere biologique et utilisations de celle-ci
KR20160020552A (ko) 척추측만증 및 척추측만증 진행에 대한 마커로서 Gi 단백질 인산화, 척추측만 개체에서 GiPCR 신호전달을 증가시키는 방법
WO2008064264A2 (fr) Procédés in vivo d'identification et de criblage de composés qui modulent la liaison de calstabine à un récepteur de ryanodine
US20170087145A1 (en) Gapdh cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness
US20020045564A1 (en) Methods of modulating muscle contraction
WO2016088125A1 (fr) Compositions et méthodes de traitement de maladies dégénératives de la rétine
WO2008066744A9 (fr) Procédés et compositions de traitement et de prévention des lésions de la moelle épinière et d'autres maladies ou lésions cérébrales
US20160114006A1 (en) Compositions and methods for treatment of retinal degenerative diseases
Arulmani Calcitonin Gene-Related Peptide and Migraine: Implications for Therapy
Ke et al. The Effects of Progressive Heart Failure on the Na/K ATPase and Intracellular Calcium Regulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07795615

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07795615

Country of ref document: EP

Kind code of ref document: A2